The role of ADAMTS13 in acute myocardial infarction
| Autor: | Matthijs F. Jansen, Jeroen A.M. Beliën, Elise S. Eerenberg, Bert-Jan H. van den Born, Paul F. Teunissen, Ruben Tijssen, Niels van Royen, Maurits R. Hollander, Marcel Levi, Mohamed F.A. Aly, Hans W.M. Niessen, Peter M. van de Ven, Otto Kamp, Pieter W. Kamphuisen, Joost C. M. Meijers |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC), Vascular Ageing Programme (VAP), Cardiology, ICaR - Ischemia and repair, Pathology, Epidemiology and Data Science, ICaR - Heartfailure and pulmonary arterial hypertension, Cardio-thoracic surgery, Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, Experimental Vascular Medicine, Graduate School, Other departments |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Time Factors Physiology medicine.medical_treatment Sus scrofa Myocardial Infarction Infarction 030204 cardiovascular system & hematology von Willebrand factor 0302 clinical medicine hemic and lymphatic diseases Medicine REPERFUSION Prospective Studies Myocardial infarction Middle Aged NO-REFLOW PHENOMENON Magnetic Resonance Imaging ADAMTS13 Recombinant Proteins ISCHEMIA Treatment Outcome Injections Intra-Arterial cardiovascular system Cardiology Female Cardiology and Cardiovascular Medicine medicine.medical_specialty VON-WILLEBRAND-FACTOR Ischemia PERCUTANEOUS CORONARY INTERVENTION ADAMTS13 Protein Ischemia-reperfusion injury Myocardial Reperfusion Injury Acute myocardial infarction ISCHEMIA/REPERFUSION INJURY 03 medical and health sciences Reperfusion therapy Physiology (medical) Internal medicine Animals Humans cardiovascular diseases PLASMA-LEVELS SUBARACHNOID HEMORRHAGE Aged Cardiac Biology and Remodelling business.industry Myocardium Percutaneous coronary intervention No reflow Original Articles medicine.disease MODEL Disease Models Animal 030104 developmental biology Conventional PCI No reflow phenomenon MICROVASCULAR OBSTRUCTION ST Elevation Myocardial Infarction business Biomarkers |
| Zdroj: | Cardiovascular Research, 111(3), 194-203. Oxford University Press Eerenberg, E S, Teunissen, P F A, van den Born, B-J, Meijers, J C M, Hollander, M R, Jansen, M, Tijssen, R, Belien, J A M, van de Ven, P M, Aly, M F, Kamp, O, Niessen, H W, Kamphuisen, P W, Levi, M & van Royen, N 2016, ' The role of ADAMTS13 in acute myocardial infarction : cause or consequence? ', Cardiovascular Research, vol. 111, no. 3, pp. 194-203 . https://doi.org/10.1093/cvr/cvw097 Cardiovascular Research Cardiovascular research, 111(3), 194-203. Oxford University Press |
| ISSN: | 0008-6363 |
| Popis: | AIMS: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, is a metalloprotease that cleaves von Willebrand factor (VWF). There is considerable evidence that VWF levels increase and ADAMTS13 levels decrease in ST-elevation myocardial infarction (STEMI) patients. It is unclear whether this contributes to no reflow, infarct size, and intramyocardial haemorrhage (IMH). We aimed to determine the role of ADAMTS13 in STEMI patients and to investigate the benefits of recombinant ADAMTS13 (rADAMTS13) in a porcine model of myocardial ischaemia-reperfusion.METHODS AND RESULTS: In 49 consecutive percutaneous coronary intervention (PCI)-treated STEMI patients, blood samples were collected directly after through 7 days following PCI. Cardiac magnetic resonance was performed 4-6 days after PCI to determine infarct size and IMH. In 23 Yorkshire swine, the circumflex coronary artery was occluded for 75 min. rADAMTS13 or vehicle was administered intracoronary following reperfusion. Myocardial injury and infarct characteristics were assessed using cardiac enzymes, ECG, and histopathology. In patients with IMH, VWF activity and VWF antigen were significantly elevated directly after PCI and for all subsequent measurements, and ADAMTS13 activity significantly decreased at 4 and 7 days following PCI, in comparison with patients without IMH. VWF activity and ADAMTS13 activity were not related to infarct size. In rADAMTS13-treated animals, no differences in infarct size, IMH, or formation of microthrombi were witnessed compared with controls.CONCLUSIONS: No correlation was found between VWF/ADAMTS13 and infarct size in patients. However, patients suffering from IMH had significantly higher VWF activity and lower ADAMTS13 activity. Intracoronary administration of rADAMTS13 did not decrease infarct size or IMH in a porcine model of myocardial ischaemia-reperfusion. These data dispute the imbalance in ADAMTS13 and VWF as the cause of no reflow. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|